Partial complementation of the Fanconi anemia defect upon transfection by heterologous DNA. Phenotypic dissociation of chromosomal and cellular hypersensitivity to DNA cross-linking agents
- PMID: 2265827
- DOI: 10.1007/BF00197697
Partial complementation of the Fanconi anemia defect upon transfection by heterologous DNA. Phenotypic dissociation of chromosomal and cellular hypersensitivity to DNA cross-linking agents
Abstract
Transfectants obtained by mouse DNA-mediated gene transfer in Fanconi anemia (FA) primary fibroblasts from the genetic complementation groups A and B were examined for the frequencies of chromosomal aberrations and cytotoxicity following treatments by cross-linking agents. Cells from group A (FA 150), which is the most sensitive to such agents, are partially corrected for both the chromosomal and cellular hypersensitivity to 8-methoxypsoralen photoaddition. In contrast, after treatment with mitomycin C (MMC), only the chromosomal sensitivity is re-established to a near normal level. The opposite is true for FA group B cells (FA 145), i.e. cell survival to MMC is partially corrected, whereas the frequency of MMC-induced chromosomal aberration remains close to that of the untransfected cells. The partial phenotypic correction of the two end points examined is interpreted as indicating either a gene dosage effect or the necessity of introducing more than one gene type in order to achieve complete recovery of a normal phenotype. The phenotypic dissociation between the clastogenic and cellular hypersensitivity to cross-linking agents may offer the opportunity of isolating separately the responsible gene(s) by conventional rescue techniques.
Similar articles
-
Cocultivation of Fanconi anemia cells and of mouse lymphoma mutants leads to interspecies complementation of chromosomal hypersensitivity to DNA cross-linking agents.Hum Genet. 1990 May;84(6):517-21. doi: 10.1007/BF00210801. Hum Genet. 1990. PMID: 2110930
-
Abnormal response to DNA crosslinking agents of Fanconi anemia fibroblasts can be corrected by transfection with normal human DNA.Proc Natl Acad Sci U S A. 1986 Sep;83(18):7034-8. doi: 10.1073/pnas.83.18.7034. Proc Natl Acad Sci U S A. 1986. PMID: 3092225 Free PMC article.
-
Two complementation groups of Fanconi's anemia differ in their phenotypic response to a DNA-crosslinking treatment.Hum Genet. 1987 Jan;75(1):45-7. doi: 10.1007/BF00273837. Hum Genet. 1987. PMID: 3804331
-
Fanconi anemia pathway--the way of DNA interstrand cross-link repair.Pharmazie. 2013 Jan;68(1):5-11. Pharmazie. 2013. PMID: 23444773 Review.
-
Molecular and cellular biology of Fanconi anemia.Am J Pediatr Hematol Oncol. 1992 May;14(2):177-85. doi: 10.1097/00043426-199205000-00015. Am J Pediatr Hematol Oncol. 1992. PMID: 1530124 Review.
Cited by
-
Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. I. Involvement of interleukin-6.Hum Genet. 1992 Apr;89(1):42-8. doi: 10.1007/BF00207040. Hum Genet. 1992. PMID: 1577464
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources